Study Compares BBB-Crossing AAV Capsids for Efficient Central Nervous System Delivery

A new study in mice has sharpened one of gene therapy’s most stubborn problems: getting therapeutic genetic material across the blood–brain barrier without leaving large amounts of viral vector behind in the rest of the body. Researchers compared three engineered adeno-associated virus, or AAV, capsids—PHP.eB, CNSRCV300 and BI-hTFR1—with the conventional AAV9 platform after intravenous delivery. Their results suggest that the right viral shell can substantially improve access to the brain, but also show that even vectors designed to target the central nervous system can persist in peripheral organs, particularly the liver. The findings highlight both the promise and the safety challenge of systemic gene delivery for neurological disease.

The blood–brain barrier is formed by tightly connected cells lining the brain’s blood vessels, supported by pericytes, astrocytes and specialized molecular transport systems. Its primary role is protective: it limits the entry of toxins, pathogens and many medicines from the bloodstream into neural tissue. That same selectivity, however, makes it difficult to deliver gene therapies to the brain. Injecting a treatment directly into brain tissue or the fluid surrounding the spinal cord can bypass the barrier, but those approaches are invasive and may not distribute genetic material evenly throughout the central nervous system. An intravenous treatment that could circulate through the body and selectively reach neurons would therefore represent a major advance.

AAVs are among the leading vehicles for gene therapy because they can carry genetic instructions into cells while generally producing relatively mild immune reactions compared with some other viral platforms. AAV particles consist of a protein capsid surrounding a DNA payload. The capsid determines, in part, which tissues the particle can bind to, enter and persist within. Researchers can also alter the promoter, a regulatory DNA sequence that controls when and where the delivered gene is expressed. In this study, the team examined both components together, asking not only which capsids reached the brain most efficiently, but also whether promoter choice could reduce unwanted gene activity in organs outside the nervous system.

The researchers administered the candidate vectors intravenously to mice and used reporter genes to track delivery and expression. Reporters are molecular markers that produce readily measured signals, allowing scientists to map where a vector has traveled and where its genetic cargo has become active. The experiments used the broadly active CAG promoter as well as the neuron-specific hSyn promoter. CAG is commonly used when strong expression across many cell types is desired. By contrast, hSyn is associated primarily with neuronal gene activity, making it useful for testing whether a vector that reaches multiple organs can nevertheless restrict transgene production mainly to neurons.

Compared with AAV9, the two capsids PHP.eB and CNSRCV300 showed enhanced penetration of the blood–brain barrier and stronger transduction of brain tissue. Transduction refers to the process by which a viral vector introduces genetic material into a cell and enables that material to function. The study also found that these capsids displayed a predominant neuronal tropism, meaning that their activity in the brain favored neurons over other neural or tissue cell types. This distinction matters because many neurological disorders arise from defects in neurons, although other cells—including astrocytes, oligodendrocytes and microglia—can also be important therapeutic targets. A capsid that enters the brain efficiently but reaches the wrong cell population may still be poorly suited to a particular disease.

The promoter results revealed a trade-off between potency and selectivity. Relative to CAG-driven expression, the neuron-specific hSyn promoter slightly reduced cerebral transgene expression. In other words, the brain signal was somewhat weaker when the genetic payload was placed under neuronal control rather than the more broadly active promoter. Yet hSyn markedly reduced expression in peripheral tissues. This indicates that promoter engineering can provide an additional layer of biological targeting after a vector has entered a cell. The capsid influences where the particle goes, while the promoter helps determine whether the payload is switched on in that location.

That distinction became critical when the team looked beyond reporter expression and examined the physical distribution of the vectors. Immunofluorescence, quantitative polymerase chain reaction and Western blotting all provided evidence that AAV remained in peripheral tissues, including the liver. Immunofluorescence uses labeled antibodies to visualize proteins or cellular signals in tissue sections. Quantitative PCR measures the abundance of specific DNA sequences, allowing researchers to estimate how much vector-derived genetic material is present. Western blotting detects particular proteins and can help establish whether a delivered gene is producing its intended product. Together, these tests indicated that a low level of peripheral gene expression does not necessarily mean that the viral particles themselves have been eliminated from organs outside the brain.

Among the candidates, CNSRCV300 produced what the researchers described as the most favorable balance: robust central nervous system transduction with minimal peripheral accumulation. That combination could give the capsid a stronger safety profile than vectors that reach the brain but distribute more heavily to other organs. The liver is especially important in systemic AAV therapy because intravenously delivered particles commonly pass through and accumulate there. Hepatic exposure can create safety concerns through immune responses, unintended expression, cellular stress or difficulty controlling the biological effects of the therapy. The study does not establish that CNSRCV300 is safe for human use, but it identifies a measurable design goal for future vector development: maximizing brain delivery while minimizing the amount of vector deposited elsewhere.

The findings also challenge a tempting assumption about tissue-specific promoters. A neuron-specific promoter can reduce off-target expression, but it cannot prevent a capsid from physically reaching or remaining in peripheral organs. This means safety cannot be assessed solely by measuring where the therapeutic protein is produced. Researchers must also quantify vector genomes and examine the persistence of the capsid or its genetic payload in tissues throughout the body. The authors’ conclusion is that AAV targeting is co-regulated by capsid properties and promoter characteristics, rather than controlled by either element alone. In practical terms, an effective brain-directed therapy may require coordinated optimization of the viral shell, the regulatory DNA, the therapeutic payload and the dose.

The work provides a systematic framework for screening AAV vectors intended for disorders of the central nervous system, while underscoring the gap between promising mouse data and clinical application. Biology that enables a capsid to cross the mouse blood–brain barrier may not translate directly to humans, whose vascular architecture, receptor distribution and immune responses differ. Some engineered capsids can also behave differently across species, making human-relevant testing essential. The study was performed under approved animal protocols and was supported by the Lingang Laboratory Project. Its most important message is therefore not that a universal brain-delivery vector has been found, but that future gene therapies will need to treat distribution and safety as inseparable engineering problems. Better access to the brain is valuable only when it is accompanied by precise control over where the vector travels, where the gene is expressed and how long both remain in the body.